A patient by name Mahesh whose age is 60 years presented with hypercellulor Bone marrow, Peripheral Blood smear shows pancytopenia and 15 % mycloblast cells. Most likely diagnosis is
## **Core Concept**
The patient's presentation with a hypercellular bone marrow, pancytopenia on the peripheral blood smear, and the presence of 15% myeloblast cells points towards a diagnosis of bone marrow failure or a myeloproliferative/myelodysplastic disorder. This profile is suggestive of a condition where there's an issue with the maturation of blood cells.
## **Why the Correct Answer is Right**
The correct answer, **. Refractory Anemia with Excess Blasts (RAEB)**, also known as Myelodysplastic Syndrome (MDS) with excess blasts, fits this clinical picture well. Myelodysplastic Syndromes are a group of disorders caused by poorly formed or dysfunctional blood cells, typically leading to various forms of cytopenia. The presence of 15% myeloblasts in the bone marrow is diagnostic of RAEB, which falls under the MDS category. This condition is characterized by ineffective hematopoiesis, leading to a hypercellular bone marrow with peripheral cytopenias.
## **Why Each Wrong Option is Incorrect**
- **Option A:** Acute Myeloid Leukemia (AML) typically requires ≥20% myeloblasts in the bone marrow or blood for diagnosis. While the patient's myeloblast percentage is high, it's below the threshold for AML.
- **Option B:** Chronic Myeloid Leukemia (CML) usually presents with a very high white blood cell count (leukocytosis) due to an increased number of mature and immature granulocytes, not pancytopenia.
- **Option C:** Aplastic Anemia is characterized by a hypocellular bone marrow, which contrasts with the hypercellular marrow seen in this patient.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that Myelodysplastic Syndromes (MDS) can progress to Acute Myeloid Leukemia (AML), and the risk of progression is higher in cases with a higher percentage of blasts, such as RAEB. The International Prognostic Scoring System (IPSS) and its updated version (IPSS-R) are tools used to predict the risk of progression to AML and survival in patients with MDS.
## **Correct Answer:** . Refractory Anemia with Excess Blasts (RAEB)